Does Cosentyx Reduce Vaccine Response in Adults?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to vaccines. Clinical trials show it reduces antibody production against certain vaccines in adults.[1]
In a randomized study of 243 adults on Cosentyx, seroconversion rates to the Tdap vaccine dropped to 37-42% (vs. 79-88% in placebo), and tetanus protection was lower (65-74% vs. 95%). Pneumococcal vaccine response was also weaker.[2]
Which Vaccines Are Most Affected?
Live vaccines like MMR, varicella, and oral polio are contraindicated due to immunosuppression risk. Inactivated vaccines (flu, COVID-19, pneumococcal, Tdap) show reduced efficacy, especially early in treatment. Pre-treatment vaccination is recommended for optimal response.[1][3]
COVID-19 vaccines: Real-world data indicate Cosentyx lowers neutralizing antibody levels post-mRNA vaccination, though breakthrough infections occur similarly to other biologics.[4]
Timing Recommendations for Vaccination
Start vaccines 4-6 weeks before Cosentyx if possible. During treatment, inactivated vaccines are safe but less effective—booster doses may help. Avoid live vaccines entirely.[1][5]
Post-treatment: Immune recovery takes weeks to months; revaccination may be needed.[3]
Patient Risks and Real-World Impact
Adults on Cosentyx face higher infection risks if unvaccinated or poorly responsive. No increased severe COVID-19 hospitalization vs. non-biologic users, but antibody waning is faster.[4]
Monitor titers for high-risk patients (e.g., elderly). Rheumatology guidelines advise annual flu shots despite reduced efficacy.[5]
Comparisons to Other Biologics
| Biologic | Vaccine Impact (Tdap Example) | Live Vaccine OK? |
|----------|-------------------------------|------------------|
| Cosentyx (IL-17i) | Moderate reduction | No |
| Humira (TNF-i) | Mild-moderate reduction | No |
| Stelara (IL-12/23i) | Mild reduction | No |
| Dupixent (IL-4/13i) | Minimal impact | Yes[6] |
IL-17 inhibitors like Cosentyx have stronger effects on T-cell vaccines than TNF inhibitors.[2][6]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: JAMA Dermatol 2018; Cosentyx Vaccine Study
[3]: ACR Guidelines on Vaccinations in Rheumatic Diseases
[4]: Ann Rheum Dis 2022; Biologics and COVID Vaccines
[5]: EULAR Vaccine Recommendations
[6]: Head-to-Head Biologic Vaccine Trials (DrugPatentWatch.com)